References
- Schirmer P, Holodniy M. Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin. Drug Saf.8(3), 357–371 (2009).
- Buxton RC, Edwards B, Juo RR et al. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem.280(2), 291–300 (2000).
- Johnson JA, Li JF, Wei X et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med.5(7), e158 (2008).
- Deyde VM, Sheu TG, Trujillo AA et al. Detection of molecular markers of drug resistance in the 2009 pandemic influenza A (H1N1) viruses using pyrosequencing. Antimicrob. Agents Chemother.54(3), 1102–1110 (2010).
- van der Vries E, Jonges M, Herfst S et al. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J. Clin. Virol.47(1), 34–37 (2010).
- van Asten L, van der Lubben M, van den Wijngaard C et al. Strengthening the diagnostic capacity to detect Bio Safety Level 3 organisms in unusual respiratory viral outbreaks. J. Clin. Virol.45(3), 185–190 (2009).
- Meijer A, Beerens A, Claas E et al. Preparing the outbreak assistance laboratory network in The Netherlands for the detection of the influenza virus A (H1N1) variant. J. Clin. Virol.45(3), 179–184 (2009).